Overview

Phase IIIB Subcutaneous Missed Dose Study

Status:
Completed

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to determine whether subcutaneous abatacept administered to patients with rheumatoid arthritis is associated with increased immunogenicity or increased safety events upon withdrawal and reintroduction.

Phase:

Phase 3

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Abatacept